Medically reviewed by Mary Choy, PharmDMedically reviewed by Mary Choy, PharmD Trileptal (oxcarbazepine) is an anticonvulsant drug approved by the U.S. Food and Drug Administration (FDA) to treat ...

Trileptal is an anti-seizure medication that doctors may prescribe off-label for people with bipolar disorder. It is the branded version of oxcarbazepine and may help treat mania and depression.

April 20, 2005 -- The U.S. Food and Drug Administration (FDA) and Novartis Pharmaceuticals Corp have warned healthcare professionals of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal ...

Oxcarbazepine 300mg/5mL; plum-lemon flavor; contains alcohol. Off-white to slightly brown or slightly red suspension. Available in amber glass bottles containing 250 mL of oral suspension. Supplied ...

Novartis AG’s epilepsy drug Trileptal has a new warning about life-threatening skin reactions reported by patients who took the medicine, the company and the Food and Drug Administration said.

PISCATAWAY, N.J., Dec. 5, 2022 /PRNewswire/ -- Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals"), announced today the U.S. approval of a generic version of Trileptal® (oxcarbazepine) oral ...

HAWTHORNE Taro announced Wednesday that it has settled a patent lawsuit with Novartis and will launch oxcarbazepine tablets, the generic version of Novartis’ Trileptal. Oxcarbazepine tablets are ...

Novartis will pay a $185 million fine for promoting off-label uses of the antiepilepsy drug oxcarbazepine (Trileptal) and another $237.5 million in civil penalties to settle a suit involving Trileptal ...

BASEL, Switzerland, Jan 26 (Reuters) - Novartis will plead guilty to violating U.S. laws relating to potential off-label marketing and promotion of an epilepsy treatment and pay a $185 million fine, ...

Two Indian pharma companies got the FDA's approval to sell generic forms of the Novartis epilepsy drug Trileptal. Sun Pharma and Glenmark Pharmaceuticals, both based in Mumbai, are OK'd to market the ...

PHILADELPHIA - A criminal information1 was filed today against Novartis Pharmaceuticals Corporation ("NPC") for the off-label marketing of the anti-epileptic drug Trileptal, announced Assistant ...